Literature DB >> 17943963

Changing trends of research and treatment in infant neuroblastoma.

Gregory K Friedman1, Robert P Castleberry.   

Abstract

Neuroblastoma is the most common malignancy in infants and 40% of neuroblastomas are diagnosed in the first year of life. While generally neuroblastoma behaves less aggressively in this age group, tumors that have adverse biologic characteristics do not differ in their behavior from counterparts in older children. Clinical and biologic behavior of neuroblastoma in children up to 460 days of age is similar to that in children less than 1 year of age. Thus the categorization of children up to 18 months of age into risk category is critically dependent on biologic characterization and assignment to appropriate treatment intensity categories. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17943963     DOI: 10.1002/pbc.21354

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Authors:  Sara Cattelani; Giovanna Ferrari-Amorotti; Sara Galavotti; Raffaella Defferrari; Barbara Tanno; Samantha Cialfi; Jenny Vergalli; Valentina Fragliasso; Clara Guerzoni; Gloria Manzotti; Angela Rachele Soliera; Chiara Menin; Roberta Bertorelle; Heather P McDowell; Alessandro Inserra; Maria Luisa Belli; Luigi Varesio; Deborah Tweddle; Gian Paolo Tonini; Pierluigi Altavista; Carlo Dominici; Giuseppe Raschellà; Bruno Calabretta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

2.  Intraspinal Extension of Neuroblastoma: a Report of Two Cases.

Authors:  Kartik Chandra Mandal; Pankaj Halder; Bidyut Debnath; Mala Bhattacharya
Journal:  Indian J Surg Oncol       Date:  2019-11-20

Review 3.  Herpes simplex virus oncolytic therapy for pediatric malignancies.

Authors:  Gregory K Friedman; Joseph G Pressey; Alyssa T Reddy; James M Markert; G Yancey Gillespie
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

4.  LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest.

Authors:  Cristina Gamell; Alice V Schofield; Randy Suryadinata; Boris Sarcevic; Ora Bernard
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

5.  Morus alba Accumulates Reactive Oxygen Species to Initiate Apoptosis via FOXO-Caspase 3-Dependent Pathway in Neuroblastoma Cells.

Authors:  Young Hwi Kwon; Kausik Bishayee; Ataur Rahman; Jae Seung Hong; Soon-Sung Lim; Sung-Oh Huh
Journal:  Mol Cells       Date:  2015-07-03       Impact factor: 5.034

6.  Epidemiological and some clinical characteristics of neuroblastoma in Mexican children (1996-2005).

Authors:  Servando Juárez-Ocaña; Virginia Palma-Padilla; Guadalupe González-Miranda; Alicia Georgina Siordia-Reyes; Enrique López-Aguilar; Martha Aguilar-Martínez; Juan Manuel Mejía-Aranguré; Rogelio Carreón-Cruz; Mario Enrique Rendón-Macías; Arturo Fajardo-Gutiérrez
Journal:  BMC Cancer       Date:  2009-08-03       Impact factor: 4.430

7.  Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.

Authors:  Araz Marachelian; Ami Desai; Frank Balis; Howard Katzenstein; Muna Qayed; Michael Armstrong; Kathleen A Neville; Susan L Cohn; Mark Bush; Rudy Gunawan; Allison Pecha Lim; Malcolm A Smith; L Mary Smith
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-20       Impact factor: 3.333

8.  Toxicological and efficacy assessment of post-transition metal (Indium) phthalocyanine for photodynamic therapy in neuroblastoma.

Authors:  Monica Neagu; Carolina Constantin; Mircea Tampa; Clara Matei; Andreea Lupu; Emilia Manole; Rodica-Mariana Ion; Concettina Fenga; Aristidis M Tsatsakis
Journal:  Oncotarget       Date:  2016-10-25

9.  The effect of age distribution on the prognosis of retroperitoneal neuroblastoma.

Authors:  Xiaoyan Liu; Jichun Zhao; Lin Zhang; Jing Huang; Yukui Ma
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

10.  BI-2536 Promotes Neuroblastoma Cell Death via Minichromosome Maintenance Complex Components 2 and 10.

Authors:  Chiao-Hui Hsieh; Hsiang-Ning Yeh; Chen-Tsung Huang; Wei-Hsuan Wang; Wen-Ming Hsu; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.